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Summary
Background There is a high incidence of pressure ulcers in high-risk settings such
as intensive care. There is emerging evidence that the application of dressings to
pressure ulcer predilection areas (sacrum and heels) improves prevention strate-
gies.
Objectives To determine whether preventive dressings, applied to the sacrum and
heels of high-risk patients in intensive care units, in addition to standard preven-
tion, reduces the incidence of pressure ulcers.
Methods Between June 2015 and July 2018, a randomized, controlled, two-arm,
superiority pragmatic study was performed with a concealed 1 : 1 allocation to
the intervention and control group. Patients assigned to the intervention group
had dressings applied to the sacrum and heels.
Results In total, 7575 patients were screened for eligibility and 475 patients were
included and allocated to both groups. Finally, 212 patients in the intervention
group and 210 in the control group were analysed. The mean age was 635 years
and the majority of patients were male (654%). The cumulative pressure ulcer
incidence category II and above was 28% in the intervention, and 105% in the
control group (P = 0001). Compared with the control group, the relative risk in
the intervention group was 026 [95% confidence interval (CI) 011–062] and
the absolute risk reduction was 008 (95% CI 003–013).
Conclusions The results indicate that the application of dressings, in addition to
standard prevention, in high-risk intensive care unit patients is effective in pre-
venting pressure ulcers at the heels and sacrum.
What’s already known about this topic?
• Pressure ulcers are severe soft tissue injuries and wounds, which occur worldwide
in all healthcare settings.
• Despite preventive interventions, pressure ulcers still develop.
• There is emerging evidence that dressings help to prevent pressure ulcers.
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What does this study add?
• The incidence of pressure ulcers in intensive care units among high-risk patients
remains high.
• The application of dressings to the sacrum and heels, in addition to standard pre-
ventive measures, reduces the relative and absolute risks for the development of
pressure ulcers.
• The application of preventive dressings at the heels and sacrum seems to be feasible
in intensive care settings.
Pressure ulcers (PUs) are severe forms of skin and tissue
lesions caused by prolonged mechanical deformation of soft
tissues between stiff internal structures such as bones or ten-
dons and external support surfaces or medical devices. Adults
in supine and semi-Fowler position mainly develop PUs at the
heels and at the sacral area.1 PU prevalence and incidence is
high especially in high-risk settings including geriatric, long-
term or intensive care.2–4 PUs severely affect quality of life5
and in the latest Global Burden of Skin Disease Study, PUs
were assigned the highest disability index.1 PU occurrence in
healthcare settings is widely accepted as an unwanted adverse
outcome in patient care.6–8
State-of-the-art PU prevention includes the identification of
PU risk and the application of preventive measures. As mobil-
ity and activity limitations are the most important PU risk fac-
tors,9 the cornerstone of PU prevention is repositioning,
elevation and offloading of heels, early mobilization and the
use of special support surfaces.2
There is emerging evidence that the application of dressings
to PU predilection areas may help to prevent PUs.2,10,11
Preventive dressings on intact skin might reduce friction
between the skin and the support surfaces and therefore
reduce shear forces within the skin and underlying soft tis-
sues.12,13 To increase hospital patient safety, the Clinical Qual-
ity and Risk Management of the Charite – Universit€atsmedizin
Berlin (Germany) decided to investigate whether these dress-
ings are also effective in high-risk intensive care unit (ICU)
patients at its facilities.
The primary objective of this study was to determine
whether preventive multilayered soft silicone foam dressings
applied to the heels and sacrum, in addition to standard pre-
vention, reduced the cumulative PU incidence category II, III,
IV and deep tissue injury (DTI) compared with standard pre-




A randomized, controlled, two-arm, superiority pragmatic
study was performed with a 1 : 1 allocation to the
intervention or control group. The study was approved by the
local ethics committee at the Charite – Universit€atsmedizin
Berlin (approval number: EA1/190/14) and was registered at
ClinicalTrials.gov (NCT02295735) on 20 November 2014. No
important changes were made after study commencement.
Participants
ICU patients aged 18 years or older, within 6 h of admission
to an ICU, at high or very high PU risk with an expected min-
imum length of stay of at least 3 days were considered eligi-
ble. The assessment of high or very high PU risk of the ICU
patient was assessed by the research staff in close communica-
tion with the ICU staff and according to the classification of
the hospital PU prevention standard.14 According to the hospi-
tal standard, the risk assessment was based on mobility and
care dependency. Informed consent was obtained from the
patients or their legal representatives before or after inclusion
as soon as the patients or the legal representatives were able
to do so. ICU patients who were at the end of life or with
existing PUs at any stage according to the National and Euro-
pean Pressure Ulcer Advisory Panels (NPUAP/EPUAP) 2014
classification system, or trauma at the heels and sacrum, or
known allergies to the preventive dressings were excluded.
ICU patients who were positioned on air-fluidized beds and
patients who could not be repositioned owing to medical rea-
sons (e.g. cardiovascular instability) were not considered eligi-
ble, because the patient could not be moved for dressing
applications and skin inspections.
Settings and locations
The study was conducted in a tertiary care hospital from June
2015 to July 2018 at the Charite – Universit€atsmedizin Berlin,
Germany. Patients were recruited from seven ICUs including
surgical, cardiovascular, gastroenterology, nephrology, anaes-
thesiology and neurology ICUs. The mean number of beds
per ward was 14 (range 10–24). Study personnel walked
rounds twice daily (including weekends and holidays) on all
participating ICUs between 0700 h and 1900 h enabling a
daily recruitment period of 18 h. In the case of a potentially
eligible patient, a researcher from the study team checked the
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inclusion and exclusion criteria using a screening form. If eli-
gible, the patient was included and randomized.
Interventions
All included patients from ICUs who had high or very high
PU risk received PU prevention according to the hospital stan-
dard. Besides PU risk scoring, the standard care included
instructions for skin inspection within 6 h after admission
and, depending on the risk, the following preventive mea-
sures: (i) patient information, (ii) daily skin inspection at least
twice daily, (iii) mobilization, (iv) use of special support sur-
faces, (v) repositioning and (vi) heel flotation.14
For patients in the intervention group, dressings were
applied on both heels (Mepilex Border Heel, M€olnlycke
Health Care, Gothenburg, Sweden) and on the sacral areas
(Mepilex Border Sacrum, M€olnlycke Health Care) according
to manufacturer’s instructions in addition to the standard care.
Care was taken that the dressings were applied correctly and
that no other skincare products were used between the skin
and the dressings. The dressings were renewed every 3 days
and the skin underneath the dressings was checked daily. In
cases where dressings became soiled or dislodged, they were
changed immediately. Dressings remained on the skin during
the whole study period, including transfers to other wards or
transfers for diagnostic or therapeutic purposes.
In both groups, included patients were followed up at least
once daily by the study team in order to ensure study compli-
ance, correct dressing use and fit, to assess the skin and to
document the health condition and PU risk.
The follow-up visits stopped when one of the following
occurred: (i) the patient was no longer at ‘high’ or ‘very
high’ PU risk and no sacral or heel PU developed, (ii) a heel
or sacral PU that developed within the study period had com-
pletely healed, (iii) an adverse event (AE) related to the pre-
ventive dressings occurred, (iv) the patient wished to
withdraw, (v) a severe form of protocol violation occurred
(e.g. nonwearing of the dressings for more than 24 h), (vi)
the patient died or (vii) the patient was transferred to another
setting outside the university hospital campus or was dis-
charged.
Kick-off meetings at the participating ICUs, daily follow-up
visits by the study team and monthly status reports on recruit-
ment at the participating ICUs were provided to improve
adherence to the study protocol. In addition, laminated patient
cards were posted at or near beds. These cards included essen-
tial study information and contact details of the study team,
and served as a reminder.
Outcomes
The primary outcome was the cumulative incidence of PU cat-
egory II, III, IV, unstageable and DTI at heels or sacrum. PUs
were categorized according to the NPUAP/EPUAP 2014 classi-
fication system.2 The occurrence of a new PU of any category
was assessed and documented daily during the study period.
Members of the study team, independently from the ward
staff, conducted skin and tissue inspections daily and were
aware of the group assignment. The study team members
were instructed about the study design, procedures, data col-
lection and documentation methods before carrying out the
inspections. A 1-h skin inspection and PU classification
instruction was provided, followed by an online examination
(PuClas3)15 for all researchers performing skin examinations.
Secondary outcomes were the incidence density (propor-
tions of PUs per 1000 bed days) of PU category II and higher,
the cumulative incidence and incidence density of PU category
I (nonblanchable erythema) and higher. The total number of
days free of PU categories I or II and higher at the heels and
sacrum was also measured.
PU risk was measured according to the hospital standard
and the Braden scale. The Braden scale is a standardized six-
item PU risk assessment instrument with scores ranging from
6 (high PU risk) to 23 (no PU risk). The reliability of this
score in the study setting has been previously confirmed.16
Other variables assessed at baseline were demographic char-
acteristics (age, sex, smoking status), body mass index (BMI),
main medical diagnoses at admission and prior to the ICU stay
(coded according to the International Classification of Diseases
10), presence of diabetes mellitus or tetraplegia, the length of
stay in the emergency department (ED) or on peripheral
wards prior to the ICU stay. Data regarding urine and/or stool
incontinence, type of support surfaces and positioning inter-
vals were observed daily by direct observations. The skin pho-
totype of participants was classified according the Fitzpatrick
classification ranging from I (white skin, never tans) to VI
(dark brown/black skin, tans deeply).17,18
In the intervention group, harms were classified into device
deficiency (DD), AEs and adverse device effect. A DD was
defined as inadequacy of a medical device with respect to its
identity, quality, durability, reliability, safety or performance.
An AE was defined as any untoward medical occurrence, unin-
tended disease, injury or clinical sign related to the investiga-
tional dressings.
Sample size
A study of independent cases and controls with one control
per case was planned. Available data from the hospital quality
management system indicated that the average PU incidence at
the ICUs was 006 per month. We expected a cumulative PU
incidence for experimental participants to be 001 [relative
risk (RR) 017]. In order to test this hypothesis, 211 experi-
mental patients and 211 control patients were needed to reject
the null hypothesis that the PU incidence in the intervention
and control groups is equal with a probability (power) of 08.
The type I error probability associated with this test of the
null hypothesis is 005 (two-sided). We used the v2-test
statistic to evaluate this null hypothesis. To prevent a possible
loss of follow-up of 10%, we planned to include 464 patients.
An interim analysis was conducted after 50% of the sample
(n = 232) had completed the study. We planned to stop the
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study after the interim analysis, if the conditional power based
on the observed data after 50% of recruitment was less than
the 60% required to reject the null hypothesis.19
Randomization
A simple randomization with a 1 : 1 allocation as per com-
puter-generated randomization table was used. The random-
ization table was created independently from the study team
at the Department of Biometry and Clinical Epidemiology at
the Charite – Universit€atsmedizin Berlin. Sequentially num-
bered, opaque, sealed envelopes containing the group assign-
ment were prepared and used. The data manager, who was
not involved in any study procedures, prepared the envelopes.
On the morning of the daily recruitment, approximately five
to eight consecutive envelopes were taken for potential use
during the day. After a patient was included and baseline data
were collected, the study personnel opened the next num-
bered envelope and the patient was allocated to the interven-
tion or control group. Based on the randomization logs there
was no evidence of selection bias.
Blinding
Owing to the nature of the intervention, caregivers and the
study team were not blinded. The data manager was blinded
throughout the study.
Statistical methods
Depending on the levels of measurement (nominal, ordi-
nal, continuous) variables were described using absolute
and relative frequencies or arithmetic means, medians and
spread parameters (minimum, maximum, interquartile
ranges and SDs).
The primary outcome PU incidence category II, III, IV,
DTI at the heels and/or sacrum was compared using the
v2-test. This was the main analysis of this primary outcome.
An a level of 5% (two-sided) was applied. Kaplan–Meier
analysis was used to compare the times to development of
a new PU between groups. A generalized linear model
(GEE) analysis was conducted to adjust for different baseline
covariates regarding the primary outcome. All statistical
analyses were based on the intention-to-treat (ITT) princi-
ple. The ITT population included all participants who gave
informed consent prior to or after randomization. Postran-
domization exclusions occurred only for reasons of missing
consent.
Secondary outcomes were analysed in a similar way. The
v2-test or t-tests were applied to compare groups. In cases
where the normality assumption was violated, the Mann–
Whitney U-test was used rather than t-test. Results of these
secondary outcomes were considered exploratory. All statistical




In total, 7575 ICU patients were screened for eligibility
and 475 ICU patients (63%) were included. Overall, 238
patients were allocated to the intervention and 237 patients
were assigned to the control group. In total, 23 patients
(48%) personally declined participation after randomiza-
tion. Additionally, 17 patients in the intervention group
and 13 patients in the control group were excluded after
randomization, e.g. because seeking informed consent was
not possible owing to death and/or nonavailability of legal
representatives. Finally, 422 patients (888%) were anal-
ysed, these were all patients who provided informed con-
sent. A detailed description of the participant flow is
shown in Figure 1.
Recruitment
The recruitment period was from 1 June 2015 to 26 July
2018. The study stopped after the required number of patients
had been included.
Baseline data
Demographic and sample characteristics are shown in Table S1
(see Supporting Information). The mean ( SD) age of ICU
patients was 635 years ( 154). The majority of the ICU
patients were male (654%), the mean BMI was 265 kg m2
( 49) and most ICU patients had a Fitzpatrick skin photo-
type of II (751%). In total, 171 ICU patients (405%) were
affected by diabetes mellitus and 10 patients (24%) had
tetraplegia. Besides a slight imbalance regarding the propor-
tions of sex, both groups were comparable.
Outcomes and estimation
Data relating to 422 ICU patients were analysed. Patients were
followed up for an average of 126 days ( 127) (Table 1).
The longest follow-up period was 130 days. The Mann–Whit-
ney U-test showed that the follow-up periods were statistically
significantly different between the intervention and control
groups (P = 0006).
Primary outcome
Numbers and proportions of all incident PU cases and cate-
gories are shown in Table 2. The cumulative incidence of PUs
ranging from category II to DTI was 66% (28 of 422). The
difference between groups was statistically significant (P =
0001). The RR in the intervention group compared with the
control group was 026 (95% CI 011–062). The absolute
risk reduction was 008 (95% CI 003–013). Therefore, the
number needed to treat was 123 (95% CI 299–78).
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Fig 1. Flowchart outlining the flow of participants throughout the study.
PU, pressure ulcer; ICU, intensive care unit; BMI, body mass index.
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Secondary outcomes
The cumulative PU incidence of PUs ranging from category I
to DTI was 81% (34 of 422) for the whole sample (Table 2).
The most common location was the sacral area and most PUs
were category II. The cumulative incidence was 28% (six of
212) in the intervention group and 133% (28 of 210) in the
control group. This difference was statistically significant (P <
0001). No PU classified as category IV was identified in
either group.
The PU incidence rates are shown in Table 3. The differ-
ences between groups were statistically significant (P = 0001)
when category I PUs were included/excluded.
The mean ( SD) time to PU development (category II to DTI)
for the whole sample was 121 days ( 122). In the intervention
group, the mean time for PU development was 108 days (
101) and 135 days ( 138) for the control group. The differ-
ence between the groups was statistically significant (P = 0025).
The Kaplan–Meier plots for PU categories II to DTI are
shown in Figure 2. The mean survival time was 607 days
[SEM 41, 95% confidence interval (CI) 527–687] in the
intervention group and 890 days (SEM 98, 95% CI 697–
1082) in the control group. The difference between the two
groups was statistically significant (P = 001).
Results of the GEE analysis regarding the development of
PUs ranging from category II to DTI in both groups are
Table 1 Follow-up period
Intervention








Mean (SD) 110 (103) 143 (146) 126 (127) 0006
Median (IQR) 8 (4–14) 10 (6–17) 9 (5–16)
Min–max, days 1–68 1–130 1–130
IQR, interquartile range.
Table 2 Pressure ulcer (PU) location and incidence (cumulative)
Intervention
group (n = 212)
Control group
(n = 210) Total (n = 422)
Pearson v2-test,
P-values
PU incidence, n (%) 6 (28) 28 (133) 34 (81) < 0001
PU sacrum, n (%) 6 (28) 23 (110) 29 (69) –
Category I 0 4 4 –
Category II 4 10 14 –
Category III 0 1 1 –
Category IV 0 0 0 –
Category DTI 2 8 10 –
PU heel right, n (%) 0 (00) 2 (10) 2 (05) –
Category I 0 1 1 –
Category II 0 1 1 –
Category III 0 0 0 –
Category IV 0 0 0 –
Category DTI 0 0 0 –
PU heel left, n (%) 0 (00) 3 (14) 3 (07) –
Category I 0 1 1 –
Category II 0 1 1 –
Category III 0 0 0 –
Category IV 0 0 0 –
Category DTI 0 1 1 –
PU categories, n (%)
PU category I 0 (00) 6 (29) 6 (14) 0013
PU category II to DTI 6 (28) 22 (105) 28 (66) 0001
PU category III to DTI 2 (09) 10 (48) 12 (28) 0006
PU category IV to DTI 2 (09) 9 (43) 11 (26) 0018
PU category DTI 2 (09) 9 (43) 11 (26) 0018
DTI, deep tissue injury.
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shown in Table 4. The model was adjusted for group alloca-
tion, follow-up time, age, diabetes mellitus and procedures
prior to being transferred to the ICU (staying in the ED, stay-
ing in the operating room, staying for diagnostic reasons).
ICU patients in the intervention group (b –1312, odds ratio
0269; P = 0006) developed statistically fewer PUs ranging
from category II to DTI compared with the control group. All
other predictors were not statistically significant.
Harms
In total, two AEs occurred. One patient reported burning
pain and warm sensation under the sacral dressing. No
signs of inflammation or impaired skin integrity were
seen. The dressing application was stopped immediately
and the patient wished to withdraw. After the product
application was stopped, the burning pain and warm sen-
sation decreased. The outer layers of the skin of another
patient peeled under the sacral dressing after application.
No signs of inflammation were seen. The product applica-
tion was not stopped and the patient terminated the
study.
Discussion
There were limitations to this study. Performance and detec-
tion bias may have occurred because patients, caregivers and
study personnel were not blinded to the study procedures
and randomized allocation. A selection bias might also have
occurred. However, because all eligible patients were screened
during the recruitment period and randomized according to
the planned order, a selection bias is considered unlikely. We
used a simple 1 : 1 randomization as per computer-generated
randomization tables. Study groups were similar regarding
demographic and other characteristics, and observed imbal-
ances regarding sex were minor. Owing to outliers, the maxi-
mum follow-up time was longer in the control group
compared with the intervention group, but the medians were
similar and an effect on the primary outcome is unlikely.
Moreover, the a-priori-defined end-of-study criteria numbers
(iii) (an AE related to the preventive dressings occurred) and
(v) (protocol violation) were not in line with the ITT princi-
ple. However, neither of these criteria were applied in the
Table 3 Pressure ulcer (PU) incidence density rate
Intervention







Incidence density rate per 1000 bed days
PU category II to DTI 78 305 191 0001
PU category II to DTI 80 376 228 < 0001
DTI, deep tissue injury.
Fig 2. Event-free survival for pressure ulcer (PU) ranging from
category II to deep tissue injury (DTI).
Table 4 Generalized linear model for the dependent variable ranging from pressure ulcer (PU) category II to deep tissue injury
Parameter b SEM
Hypothesis test
Odds ratio 95% CIWald v2-test df P-values
Group (0 = control; 1 = intervention) 1312 0478 7538 1 0006 0269 0105–0687
Follow-up time 0022 0012 3482 1 0062 1022 0999–1046
Age 0007 0014 0287 1 0592 0993 0966–1020
Diabetes mellitus (0 = no; 1 = yes) 0668 0408 2684 1 0101 1951 0877–4340
Stay in ED (0 = no; 1 = yes) 0823 0524 2464 1 0117 0439 0157–1227
Stay in operating room (0 = no; 1 = yes) 0226 0605 0139 1 0709 1253 0383–4105
Stay for diagnostic reason (0 = no; 1 = yes) 0198 0411 0232 1 0603 1219 0545–2729
Braden scale score 0025 0137 0033 1 0856 0975 0745–1276
Constant 2014 1499 1807 1 0179 0133 –
CI, confidence interval; ED, emergency department, b, regression coefficient, df, degrees of freedom.
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trial. Furthermore, we did not collect information about PUs
at body areas other than the heels and sacrum.
A major strength of this study was the pragmatic procedure.
Pragmatic studies are able to measure realistic treatment effects
in daily clinical routines compared with highly standardized
randomized controlled trials (RCTs).20 Demographic character-
istics such as age and sex are comparable to previous studies
in this setting.21–24 The proportions of postrandomization
exclusions were within the range of other RCTs in this set-
ting.13,25,26 The majority of PUs occurred at the sacral area,
which is in alignment with other published research results.23
However, patients in our sample were at higher PU risk com-
pared with other studies.4,13,23,27
As ICU care organization and staff characteristics are set-
ting-specific, generalizability to other ICUs in other regions or
countries might be limited. However, the local hospital stan-
dard PU prevention corresponds to the international state-of-
the-art approach2 and the direction of the shown treatment
effect is consistent with results of previous RCTs.11,28
Results of this pragmatic RCT indicate that the additional
use of preventive dressings at the two most important PU
predilection areas substantially reduces the development of
new PUs at these areas. The absolute risk reduction of 8% was
higher than expected, but might be explained by including
only high-risk and very high-risk ICU patients. This effect esti-
mate is based on category II PUs and above, which is a major
strength of this study compared with other RCTs in this
area.29 As category I PUs are not wounds, the clinical rele-
vance of this outcome is questionable and the measurement
error of this outcome is high.30 However, when category I
PUs were included the absolute risk reduction was 10%,
which is similar to the treatment effect of the primary out-
come and also similar to the results of a cluster RCT in high-
risk residents in aged care.29 Additionally, the adjusted analysis
for key prognostic factors showed that the allocation to the
intervention group was the only significant factor, which
strengthens our conclusions.
The principle underlying mode of action of the investigated
dressings is lower friction between the outer dressing and the
support surfaces, thus reducing shear within the skin and
underlying soft tissues.31,32 Other types of dressings are used
for PU prevention and study results are mixed.33,34 Therefore,
compared with many other areas in PU prevention research,
direct head-to-head comparisons are urgently needed to sup-
port clinical decision making.35
As the observed treatment effect is consistent with previous
study results using the same dressing13,23,29 and the AEs were
minor, we conclude that the use of the investigated dressing
in addition to standard care is effective in preventing PUs in
high-risk ICU patients. Compared with other established pre-
ventive measures, such as the use of special support surfaces,
repositioning, floating heels and mobilization,2 this additional
intervention can be easily implemented. Although the treat-
ment effect was substantial, PUs in the intervention group still
occurred. This indicates that PU prevention is still not
optimal.
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